CareDx Inc (CDNA) Major Shareholder Purchases $225,382.80 in Stock
CareDx Inc (NASDAQ:CDNA) major shareholder Neil Gagnon acquired 123,160 shares of the stock in a transaction on Thursday, March 16th. The shares were acquired at an average price of $1.83 per share, with a total value of $225,382.80. Following the purchase, the insider now owns 778,133 shares in the company, valued at $1,423,983.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
CareDx Inc (NASDAQ:CDNA) traded down 3.23% on Monday, reaching $1.50. The company’s stock had a trading volume of 69,555 shares. The stock’s 50 day moving average is $2.26 and its 200-day moving average is $3.18. The firm’s market capitalization is $31.92 million. CareDx Inc has a 52 week low of $1.48 and a 52 week high of $6.08.
Your IP Address:
An institutional investor recently raised its position in CareDx stock. Royce & Associates LP increased its position in CareDx Inc (NASDAQ:CDNA) by 72.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 426,361 shares of the company’s stock after buying an additional 178,743 shares during the period. Royce & Associates LP owned about 2.00% of CareDx worth $1,151,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 38.35% of the company’s stock.
Separately, Zacks Investment Research lowered CareDx from a “buy” rating to a “hold” rating in a research note on Monday, January 16th.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc and related companies with MarketBeat.com's FREE daily email newsletter.